Данная версия сайта не обновляется с 10.09.2018, смотрите новую версию
 

Current issue #18, 2018

29.05.2018

// Regulatory & Legal – Pharma & Medical

Government makes the first move to API manufacturing support

For nearly 2 years, pharma industry players have waited for the Russian government to issue a resolution setting out tax advantages for manufacturers using local APIs. Quite a lot of swords have been crossed in disputing over potential government support measures. A three-stage system that provided for granting unrivaled preferences to local drugs in government procurement has been discussed, and even the issue of abolishing the “odd-man-out” regulation has been raised. One way or the other, the Ministry of Industry and Trade has been firmly committed to supporting local manufacturers. Apparently, largely due to the Ministry’s position, the long-awaited document has materialized.

[PharmVestnik # 18, 29/05/2018, p. 1, cont’d p. 4]

// Regulatory & Legal – Pharma & Medical

Health experts criticize ambiguous regulatory initiatives

Drug availability is closely connected with regulatory issues. The 7th All-Russia Congress “The Right to Drug” took place as the same time as the State Duma was reviewing a bill on counter-sanctions in the second – key – reading, which had predetermined the congress’ agenda. The attendees passed their opinions on this and other hot buttons of health legislation.

[PharmVestnik # 18, 29/05/2018, p. 2]

// Pharmacy – Distributor Relationships

Distributors fed up with disappearing pharmacies-related losses

The pharmacy market is saying ‘goodbye’ to the organic development model that has until recently been most effective and transparent. And if before, by stating “I am developing organically”, the business owner meant that his/her business was honest and transparent, now the same owner has to admit that no leadership can be maintained without acquisitions. None of the distribution chain players are happy with the status quo of the pharmacy market. While pharmacies are struggling to survive, distributors tighten the screws.

[PharmVestnik # 18, 29/05/2018, p. 3]

// Regulatory & Legal – Pharma & Medical

Online drug sales to trigger off new price wars in pharmacy sector

The State Duma has been going through the second reading of the online drug sales bill when it came to a standstill. Meanwhile, both pharma and Internet companies are getting ready for approval of web-based drug sales, although they differ in their approaches to this market.

[PharmVestnik # 18, 29/05/2018, p. 5]

// Regulatory & Legal – Pharma & Medical

FAS denies administrative pressure on businesses

Most initiatives aimed to transform the pharmaceutical industry involve the Federal Antimonopoly Service (FAS). Within the framework of the recent Russian Pharmaceutical Forum hosted by the Adam Smith Conferences, Timofey Nizhegorodtsev, Head of the Department of Social Issues and Trade Control of the FAS, briefed Yury Krestinsky, Director of the Institute of Public Healthcare Development, on the methods the FAS resorted to for cutting drug prices and measures to support local manufacturers.

[PharmVestnik # 18, 29/05/2018, p. 6]

// Regulatory & Legal – Pharma & Medical

Roszdravnadzor: distributors should be responsible for quality of imported drugs

According to Mikhail Murashko, Head of the Federal Service for Consumer Rights Protection and Human Welfare (Roszdravnadzor), this year’s trend is controlling forefront dealers. When speaking at the International conference “Reglek (Drug Regulation) — EAEU 2018” hosted by the Scientific Center for Assessment of Human Medicinal Products, Mr. Murashko emphasized that the arguments of those trying to prove that manufacturers should be solely responsible for the quality of imported drugs would not be accepted. In particular, distributors will be held responsible for importing substandard products, too.

[PharmVestnik # 18, 29/05/2018, p. 7]

// R&D – Pharma & Medical

Scientific medical ideas get crushed by harsh reality of the market

Despite the growing opportunities for the implementation of R&D products to yield in-demand medical products, a vast majority of the ideas generated by universities and research institutes materialize into things no one wants. Experience proves that bringing together scientists and investors is not enough. For a project to be commercially viable, it first needs to be ‘pimped out’ and ‘packed up’.

[PharmVestnik # 18, 29/05/2018, p. 9]

// Pharma Retailing

New Pharmacy Chain 36.6 execs work on fiscal discipline

Polina KISELYOVA, Director General of Pharmacy Chain 36.6 Retail, has undergone battle testing at the recent Russian Pharmaceutical Forum. In 2013–2017, Ms. Kiselyova was Head of Marketing and Business Support at Pyatyorochka FMCG chain, an Х5 Retail Group company. Now she is getting acquainted with the pharma community. The acquaintance is somewhat difficult because of 36.6’s sensitive debt issue. PharmVestnik asks Polina Kiselyova about her impressions of the pharma sector to which she is new.

[PharmVestnik # 18, 29/05/2018, p. 10]

// Telehealth

MoH clarifies telehealth services provision issues

Recently, Russia’s Ministry of Health offered a response to the National Telehealth Association regarding the telehealth services provision procedure. Then, the Government Resolution # 555 (May 2018) put the controversial points into law. The MoH clarified that telehealth services might be provided at licensed clinics only as this type of services was referred to medical activities. All players in the digital health segment should be properly registered.

[PharmVestnik # 18, 29/05/2018, p. 11]

// Sanctions

Ukraine puts Russian pharma companies on sanction lists

While Russian deputies were thinking whether US drugs should be banned in this country, Ukraine got involved into drug-related sanctions. At that, bills have been brought in to the Verkhovna Rada of Ukraine (Ukrainian Parliament) to permit nationalization of the Russian corporate property in Ukraine as well as impose penalties for doing business with Russia.

[PharmVestnik # 18, 29/05/2018, p. 12]

// Pharma Manufacturing

Russia’s Federal Cancer Center runs in-house pharmaceutical manufacture

N.N. Blokhin Federal Cancer Center in Moscow has an animal facility, labs, state-of-the-art sterile manufacturing lines, and Quality Control of their own. However, there is next to nil information on this full-scale manufacturing facility. PharmVestnik sets out to investigate the details.

[PharmVestnik # 18, 29/05/2018, p. 14]

// Insight – Pharmacies

Rating of pharmacy chains, Q118

According to IQVIA, as of the 1st quarter 2018, a combined retail market share of the TOP10 pharmacy chains reached 41.6%, up 10.8% year over year (YoY). ASNA still leads the ranks with a 13.8% market share. The runners-up are Rigla (5.5%) and Erkapharm 4.6%. A combined retail market share of the TOP3 pharmacy chains increased by 8.1% YoY.

[PharmVestnik # 18, 29/05/2018, pp. 16-17]

// Insight – Advertising

Specialized drug advertising segment, 2017

According to Ipsos Healthcare, as of 2017, the Russian market of drug advertising in specialized printed media amounted to 2B RUB. The number of advertising blocks decreased by 4% year over year (YoY) overall. As follows from the syndicated research ‘Monitoring of drug advertising and content analysis of scientific papers in printed medical and pharmaceutical journals’ (Contenta Medical Index), both the Rx and OTC advert segments posted a slight growth in value terms: by 6% и 2%, respectively. In terms of the number of advertising blocks, the Rx segment demonstrated a 4% growth, while the OTC segment stagnated at -2% YoY.

[PharmVestnik # 18, 29/05/2018, pp. 18-19]

// Regulatory & Legal – Drug Procurement

Drug procurement to benefit of health providers and patients requires different regulations

The Southern and Volga regions are playing up the bills to make amendments to Federal Law # 44 in regards of drug procurement for health providers. The regional heads, manufacturers, and physicians state that the implementation of this law results in procurement procedures lasting for months, and that it is difficult for clinics to provide for personalized treatment, while the economic benefit from the biddings is not as high as expected.

[PharmVestnik # 18, 29/05/2018, p. 20]

// Pharma Retailing

Pharmaceutical retailers master related businesses

Gubernskie Apteki, the largest government-funded pharmacy chain east of the Urals, develops an animal health business, with profit expected by the end of 2018. This is one of the ways to keep afloat.

[PharmVestnik # 18, 29/05/2018, p. 20]

// Pharma Retailing

Apteka-City drops out of game

Federal-scale pharmaceutical retailer Rigla has acquired pharmacy chain Apteka-City (Ekaterinburg). Now the latter will operate as Zhivika. Local retail market players admit that they are often approached with a proposal to sell their businesses.

[PharmVestnik # 18, 29/05/2018, p. 21]

// Extemporaneous preparation

A renaissance of extemporaneous preparation

In some regions, compounding pharmacies are continuously closed because of low profitability, while in others they develop successfully and even generate competition. E.g., in Rostov-on-Don, a private company has recently moved into extemporaneous preparation for retail customers. Before, this company specialized in drug manufacturing for the hospital sector.

[PharmVestnik # 18, 29/05/2018, p. 21]

Регистрация скоро будет доступна на новой версии сайта.